Latest Sleep and breathing Stories
BELMONT, Calif., Jan. 23, 2012 /PRNewswire/ -- United States military veterans now have the option to use Provent(®) Sleep Apnea Therapy, a small, non-invasive nasal device for the treatment of obstructive sleep apnea (OSA). Ventus Medical, maker of Provent Therapy, today announced the U.S. Department of Veterans Affairs has granted a multi-year, Federal Supply Schedule contract that would expand access to Provent Therapy among veterans. (Photo:...
Michael Simons, DMD, a general dentist whose office is located in Tarzana, CA was instrumental in introducing legislation via the San Fernando Valley Dental Society that recognizes the importance of dentistry’s involvement in the recognition and management of sleep disordered breathing problems. This legislation clarifies the important role that dentists play in the screening for and management of sleep-breathing disorders. New York, NY (PRWEB) January 19, 2012 Michael Simons, DMD, a...
Snoring Isn’t Sexy, a leading advocate for dentistry’s participation in the recognition and management of snoring and sleep apnea, announces availability of founder Laurence Barsh, DMD for comment and analysis of Dental Sleep Medicine break-throughs and treatments. Snoring Isn’t Sexy has been a leading advocate for dentists who screen for and provide treatment solutions (in conjunction with sleep physicians) for snoring and sleep apnea and for those patients who cannot tolerate CPAP....
Snoring Isn't Sexy takes pride in the accomplishments of it members and is, therefore, pleased to announce that Dr. Jack Cherin, who provides care for patients with snoring, sleep apnea and sleep-disordered breathing, has been re-elected to serve on the Board of Directors of the American Academy of Craniofacial Pain. New York, NY (PRWEB) December 21, 2011 Snoring Isn't Sexy and Dr. Jack Cherin, a dentist in Virginia Beach, VA who practices dental sleep medicine and TMJ therapy, are...
Hypoglossal nerve stimulation (HGNS) produced marked dose-related increases in airflow in obstructive sleep apnea (OSA) patients without arousing them from sleep, according to a new study from the Johns Hopkins Sleep Disorders Center. The study suggests the potential therapeutic efficacy of HGNS across a broad range of sleep apnea severity and offers an alternative to continuous positive airway pressure (CPAP), the current mainstay of treatment for moderate to severe OSA. The effectiveness of...
BELMONT, Calif., Nov. 3, 2011 /PRNewswire/ -- Ventus Medical today announced the appointment of Sandra Gardiner to the position of Vice President and Chief Financial Officer, and Michael Lopez to the position of Vice President, Operations. "Sandy and Michael are tremendous additions to our executive team and bring outstanding leadership and broad experiences that will support our quickly expanding sales of Provent® Sleep Apnea Therapy in the U.S. and global markets," said Peter Wyles,...
ST. PAUL, Minn., Oct. 27, 2011 /PRNewswire/ -- Apnex Medical, Inc., has received CE Mark approval for its Hypoglossal Nerve Stimulation (HGNS®) System for use by people who suffer from obstructive sleep apnea (OSA). The system was approved for sale in Europe based on the positive results of two clinical studies conducted in the United States and Australia. In those studies, the majority of patients demonstrated a significant reduction in their obstructive sleep apnea as well as...
BELMONT, Calif., Oct. 17, 2011 /PRNewswire/ -- Ventus Medical today announced that the results of a large, long-term study of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA), were published in the November 2011 issue of the Journal of Clinical Sleep Medicine, an official publication of the American Academy of Sleep Medicine. (Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-b) (Photo:...
BELMONT, Calif. and BRISBANE, Australia, Oct. 3, 2011 /PRNewswire/ -- Ventus Medical is pleased to announce that its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA), is now available in Australia and New Zealand. BMedical Pty. Ltd. will be the strategic distribution partner of Provent Therapy in these countries. (Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-a) (Photo:...
The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.The findings appear online in the articles-in-press section of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine."In patients with obstructive sleep apnea who are established on CPAP treatment, withdrawal of the therapy is associated with a rapid...
